Announcement of Deputy Chief Medical Officer Appointment
Nov 15, 2022

PRINCETON, N.J., 15 November 2022 -- KBP Biosciences Co., Ltd. (“KBP Biosciences” or “KBP” or the “Company”), a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the global market, is pleased to announce James McCabe, M.D. has been appointed as Deputy Chief Medical Officer of KBP Biosciences.


(Photo:James McCabe, M.D., Deputy Chief Medical Officer of KBP)

“Dr. McCabe joined the company in 2019, and he has been instrumental in advancing Ocedurenone (KBP-5074) through its clinical development process. His work ethic, knowledge of the industry and creative thinking will greatly contribute to the continuous growth of our company,” said Dr. Zhenhua Huang, Founder and Executive Chairman of KBP Biosciences.

Dr. Julia Yang, Chief Operating Officer of KBP Biosciences, stated, “Dr. McCabe has been a vital part of the team to support the CLARION-CKD global trial. We are excited to continue working with Dr. McCabe and the team for the successful completion of CLARION-CKD as well as the strategic development of other clinical studies to support the mission of KBP Biosciences.”

Dr. McCabe has been practicing clinical nephrology in Wilmington, North Carolina for the past 25 years. The focus of his practice included hypertension, chronic kidney disease, pre and post-transplant care, critical care and dialysis. He has been involved in his hospital pharmacy and therapeutics committee for more than 20 years. He has been a Clinical Assistant Professor with the University of North Carolina, and since 2009, has been involved in numerous clinical trials to help provide patients with advanced therapies for complex medical conditions. He was a principal investigator on earlier studies of Ocedurenone (KBP-5074). Dr McCabe has a B.S. degree in Chemistry from Washington and Lee University. He received his M.D. degree from Marshall University. He completed his residency, chief residency in internal medicine and a fellowship in nephrology at Wake Forest University.

About KBP Biosciences

KBP Biosciences is a global, clinical-stage biotechnology company, headquartered in Princeton, NJ, focused on discovering, developing, and commercializing innovative small-molecule therapeutics for the treatment of serious cardiorenal and infectious diseases with large unmet needs. KBP Biosciences’ pipeline includes 4 novel drug candidates, 2 currently in clinical development covering multiple indications. CLARION-CKD, the Phase 3 clinical trial of Ocedurenone (KBP-5074), with the first indication of advanced CKD and uncontrolled hypertension, is being conducted globally.

About Ocedurenone(KBP-5074)

Ocedurenone (KBP-5074) is a non-steroidal MRA discovered and developed by KBP Biosciences. Ocedurenone (KBP-5074) selectively binds to recombinant human MRs with much higher affinity than to recombinant human glucocorticoid, progesterone, and androgen receptors which can produce antihypertensive, renal and cardioprotective effects. At present, the Phase III clinical trial of the first indications of Ocedurenone (KBP-5074), advanced CKD and uncontrolled hypertension, is being conducted globally. Other indications of Ocedurenone are planned, including CV, CKD Progression, etc. Ocedurenone (KBP-5074) has been investigated in nine clinical studies including the BLOCK-CKD Phase 2b study. Ocedurenone(KBP-5074) is expected to provide a new treatment option addressing the unmet medical needs of patients with advanced CKD and uncontrolled hypertension.

About Advanced Chronic Kidney Disease (CKD) and Uncontrolled Hypertension

Current estimates of the prevalence of CKD indicate that there are 138 million adults with CKD in China alone. Available MRAs can provide additional blood pressure control in some of these patients, but usually will increase the risk of hyperkalemia. Many patients with stage 3b/4 CKD are at their maximum tolerated dose of anti-hypertensive medications and still have uncontrolled or resistant hypertension. Therefore, there is a huge unmet medical need in these patients.

For more information about KBP Biosciences, please visit the company website at


Investor Relations:

Public Relations: